High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 715-721

  Weaver, C H ^a   Schwartzberg, L ^a   Li, W ^a   Hazelton, B ^a   West, W ^a  

^a Response Oncology Inc   (United States)

Author keywords

Autologous peripheral stem cells; High dose chemotherapy; Hodgkin's disease

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG TOLERABILITY; FEMALE; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LEUKOCYTE COUNT; LUNG TOXICITY; MALE; MORTALITY; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THROMBOCYTE TRANSFUSION; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; CRYOPRESERVATION; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HODGKIN DISEASE; HUMANS; LEUKAPHERESIS; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS;

EID: 0029922686     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Urba WJ, Longo DL. Hodgkin's disease. New Engl J Med 1992; 326: 678-687.
2. Longo DL, Duffey PL. Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.
3. Lohn A, Barnett M, Fairey RN et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991; 77: 2292-2298.
4. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871-1879.
5. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193-1199.
6. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137-1145.
7. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
8. Armitage JO, Bierman PJ, Vose JM et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991; 91: 605-611.
9. Zulian GB, Selby P, Milan S et al. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer 1989; 59: 631-635.
10. Linch DC. Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
11. Korbling M, Holle R, Haas R et al. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J Clin Oncol 1990; 8: 978-985.
12. Schwanzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
13. Gianni AM, Siena S. Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-585.
14. Tarella C, Ferrero D, Bregni M et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer 1991; 27: 22-27.
15. DeVita VT, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587-595.
16. Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252-259.
17. Klimo P, Connors JM. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1174-1182.
18. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8 year results. Ann Intern Med 1986; 104: 739-746.
19. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients following the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Star Assoc 1958; 53: 457-481.
21. Crawford SW. Critical care and respiratory failure. In: Thomas ED, Forman SJ, Blume K (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston. 1994, pp 513-526.
22. Armitage JO. Bone marrow transplantation. New Engl J Med 1994; 330: 827-838.
23. Reece DE, Phillips GL. Intensive therapy and autotransplantation in Hodgkin's disease. Stem Cells 1994; 12: 477-493.
24. Desch CE, Lasala MR, Smith TJ, Hillner BE. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy reiapse. J Clin Oncol 1992; 10: 200-209.
25. Sheridan WP, Begley CG, To LB et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105-111.
26. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-374.
27. Kessinger A, Armitage JO, Smith DM et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-1265.
28. Tourani J-M, Levy R, Colonna P et al. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol 1992; 10: 1086-1094.
29. Hagemeister FB, Tannir N, McLaughlin P et al. MIME chemotherapy (methyl-GAG. ifosfamide, methotrexate. etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 1987; 5: 556-561.
30. Barnett MJ, Man AM. Richards MA et al. OPEC chemotherapy (vincristine. prednisolone. etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease. Hematol Oncol 1987; 5: 79-82.
31. Perren TJ, Selby PJ, Milan S et al. Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease. Br J Cancer 1990; 61: 919-923.
32. Hiddemann W, Schmilz N, Pfreundschuh M et al. Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group, Cancer 1990; 66: 838-843.
33. Schulman P, McCarroll K, Cooper MR et al. Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease. A CALGB study. Med Pediatr Oncol 1990; 18: 482-486.
34. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBPCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
35. Haas R, Hohaus S, Ehrhardt R et al. Autografting with rhG-CSF mobilized blood stem cells in patients with chemosensitive malignancies. Blood 1992; 80: 238a (abstr. 942).
36. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan. and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704-711.
37. Jagganath S, Armitage JO, Dicke KA. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989; 7: 179-185.
38. Viviani S, Santoro A, Negretti E et al. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1990; 1: 123-127